Metabolic recovery after weight loss surgery is reflected in serum microRNAs.
adipose tissue
biomarkers
liver
morbid
obesity
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
04
2020
revised:
11
06
2020
accepted:
16
06
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Bariatric surgery offers the most effective treatment for obesity, ameliorating or even reverting associated metabolic disorders, such as type 2 diabetes. We sought to determine the effects of bariatric surgery on circulating microRNAs (miRNAs) that have been implicated in the metabolic cross talk between the liver and adipose tissue. We measured 30 miRNAs in 155 morbidly obese patients and 47 controls and defined associations between miRNAs and metabolic parameters. Patients were followed up for 12 months after bariatric surgery. Key findings were replicated in a separate cohort of bariatric surgery patients with up to 18 months of follow-up. Higher circulating levels of liver-related miRNAs, such as miR-122, miR-885-5 p or miR-192 were observed in morbidly obese patients. The levels of these miRNAs were positively correlated with body mass index, percentage fat mass, blood glucose levels and liver transaminases. Elevated levels of circulating liver-derived miRNAs were reversed to levels of non-obese controls within 3 months after bariatric surgery. In contrast, putative adipose tissue-derived miRNAs remained unchanged (miR-99b) or increased (miR-221, miR-222) after bariatric surgery, suggesting a minor contribution of white adipose tissue to circulating miRNA levels. Circulating levels of liver-derived miRNAs normalized along with the endocrine and metabolic recovery of bariatric surgery, independent of the fat percentage reduction. Since liver miRNAs play a crucial role in the regulation of hepatic biochemical processes, future studies are warranted to assess whether they may serve as determinants or mediators of metabolic risk in morbidly obese patients.
Identifiants
pubmed: 33115818
pii: 8/2/e001441
doi: 10.1136/bmjdrc-2020-001441
pmc: PMC7594349
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : RG/16/14/32397
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/17/10/33219
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/60/34181
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/16/3/32406
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/13/18/30207
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/19/56/34550
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: PW, SK and MM are named inventors on a licensed patent held by Medical University Innsbruck and King’s College London for the use of miR-122 as a biomarker of metabolic risk (EP2430453B1, US8546089, EP15193448.6). MM filed and licensed patent applications on miRNAs as biomarkers (EP2776580 B1, DE112013006129T5, GB2524692A, EP2576826 B, JP2013-513740). All other authors have no disclosures.
Références
PLoS One. 2010 Feb 02;5(2):e9022
pubmed: 20126310
Nat Commun. 2020 Feb 5;11(1):719
pubmed: 32024826
Cell Metab. 2018 Jan 9;27(1):252-262.e3
pubmed: 29320705
Nat Cell Biol. 2011 Apr;13(4):423-33
pubmed: 21423178
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
Pharmacol Res. 2018 Feb;128:274-287
pubmed: 29037479
BMC Obes. 2018 May 31;5:20
pubmed: 29881628
N Engl J Med. 2017 Jan 19;376(3):254-266
pubmed: 28099824
Hepatology. 2019 Jun;69(6):2636-2651
pubmed: 30779441
Diabetologia. 2013 Sep;56(9):1971-9
pubmed: 23756832
Nat Rev Dis Primers. 2015 Dec 17;1:15080
pubmed: 27188459
Sci Rep. 2016 Dec 05;6:38262
pubmed: 27917915
Int Stat Rev. 2010 Apr;78(1):40-64
pubmed: 21743766
Nature. 2017 Feb 23;542(7642):450-455
pubmed: 28199304
PLoS One. 2012;7(3):e30679
pubmed: 22427800
Obesity (Silver Spring). 2017 Jan;25(1):102-110
pubmed: 27883272
Mol Oncol. 2017 Dec;11(12):1673-1686
pubmed: 29024380
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1881-9
pubmed: 26976605
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5003-8
pubmed: 21383194
Biomarkers. 2019 Sep;24(6):499-509
pubmed: 30990364
Int J Mol Sci. 2018 Jan 16;19(1):
pubmed: 29337905
Ther Adv Endocrinol Metab. 2019 Sep 23;10:2042018819875407
pubmed: 31579501
Nature. 2004 Nov 11;432(7014):226-30
pubmed: 15538371
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
JAMA. 2018 Jan 16;319(3):279-290
pubmed: 29340677
Nucleic Acids Res. 2019 Jan 8;47(D1):D752-D758
pubmed: 30407557
World J Hepatol. 2017 Apr 28;9(12):586-594
pubmed: 28515844
Obesity (Silver Spring). 2020 Mar;28(3):493-501
pubmed: 32090516
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385722
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33
pubmed: 20304794
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
J Clin Med. 2019 Aug 15;8(8):
pubmed: 31443156
Front Endocrinol (Lausanne). 2019 Jan 04;9:773
pubmed: 30687230
Nucleic Acids Res. 2010 Nov;38(20):7248-59
pubmed: 20615901
Gut. 2015 May;64(5):800-12
pubmed: 24973316
Diabetes. 2017 Feb;66(2):347-357
pubmed: 27899485
Obes Surg. 2020 Feb;30(2):391-400
pubmed: 31728904
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
N Engl J Med. 2018 Jan 4;378(1):93-96
pubmed: 29298157
Endocr Rev. 2018 Apr 1;39(2):79-132
pubmed: 29518206
Nat Commun. 2011;2:282
pubmed: 21505438
Obesity (Silver Spring). 2019 Feb;27(2):264-271
pubmed: 30624857